A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Haberin özeti
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Güvenilir yayınların güncel haberlerini kısa açıklamalarıyla takip edin. Ayrıntılar için özgün kaynak bağlantısını açın.